RxDoctor Payments Data

Aerielle Sibert, PA

Physician Assistant · Statesville, NCNPI 1659968451

Payments from drug & device makers

$12,611in general payments, 2019–2025

Across 637 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$829
  • Johnson & Johnson$796
  • Gilead$666
  • Daiichi Sankyo Inc.$543
  • plus $4K from 21 others

What the payments were for

  • Food & beverage$12,611100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,611 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$50,961
Medicare patients
325
Services billed
3,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase52$285,319
SucraidSacrosidase15$210,394
EntyvioVedolizumab18$153,135
Humira PenAdalimumab13$104,753
Humira(Cf) PenAdalimumab12$96,389
ZenpepLipase/Protease/Amylase17$94,080
Humira(Cf)Adalimumab14$91,858
Cimzia (2 Pack)Certolizumab Pegol14$83,819
LinzessLinaclotide95$82,950
XifaxanRifaximin27$70,545
Dexlansoprazole DrDexlansoprazole115$26,937
MotegrityPrucalopride Succinate42$25,950
MovantikNaloxegol Oxalate52$25,265
ClenpiqSod Picosulf/Mag Ox/Citric Ac115$19,612
Budesonide ErBudesonide13$13,896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Humira(Cf), Linzess$4,027$460,126161 claims
QOL Medical, LLCSucraid$505$210,39415 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio, Motegrity$829$179,08560 claims
Aimmune Therapeutics, Inc.Zenpep$302$94,08017 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,674$70,54527 claims
Ferring Pharmaceuticals Inc.Clenpiq$124$19,612115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Statesville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →